Why do two non-phthalate plasticizers with nearly identical regulatory approvals perform so differently in your formulation — and cost so differently on your purchase order? The answer shapes your formulation cost, your processing setup, and your regulatory filing — especially as phthalate restrictions tighten and procurement teams scramble for compliant alternatives.
DINCH (diisononyl cyclohexane-1,2-dicarboxylate) is a non-phthalate plasticizer developed specifically for sensitive applications like medical devices, toys, and food-contact packaging. It delivers strong regulatory compliance and low migration, but it comes with processing and cost trade-offs that deserve honest evaluation. The formulation balance between safety requirements and practical performance determines whether DINCH is the right choice — or an expensive overspecification.
How DINCH Differs from Phthalate Plasticizers
DINCH is manufactured by hydrogenating DINP — essentially converting the benzene (aromatic) ring in DINP’s molecular structure into a cyclohexane ring. This single structural change is the entire basis for DINCH’s safety advantage. The aromatic ring in phthalate plasticizers is associated with endocrine disruption concerns. Removing it eliminates that specific mechanism of toxicity.
The molecular formula is C26H48O4, with a molecular weight of 424.7 g/mol and CAS numbers 166412-78-8 (Europe/Asia) and 474919-59-0 (US). Chemically, DINCH belongs to the cyclohexanoate class — it is not a phthalate, but it is structurally related to one. This distinction directly affects labeling claims. I have seen manufacturers get tripped up trying to claim “phthalate-free” when using DINP, only to face customer pushback because DINP is still classified as a phthalate. DINCH avoids that problem entirely — it is genuinely non-phthalate by both chemistry and regulation.
One practical consequence of the hydrogenation process: DINCH production depends on DINP feedstock. This creates a supply chain dependency that affects both availability and pricing.
Performance Properties and Specifications
DINCH performs as a general-purpose primary plasticizer with properties broadly comparable to DINP, though with some notable differences.
| Property | Value |
|---|---|
| Density (20 C) | 0.944-0.945 g/cm3 |
| Viscosity (20 C) | 44-60 mPa.s |
| Ester content | Min 99.5% |
| Boiling point (7 mbar) | 240-250 C |
| Flow point | -54 C |
| Acid content | Max 0.07 (DIN EN ISO 2114) |
| Phthalate content | Max 0.01% |
| Max air concentration | Less than 0.5 ug/m3 after ~600 hours at 23 C |
The low air concentration value is worth highlighting for indoor applications. Flooring manufacturers and interior product designers often overlook volatile organic compound (VOC) emissions during material selection, but this is increasingly becoming a procurement specification. DINCH’s emissions profile is exceptionally low.
The processing window for DINCH formulations requires attention. DINCH has a solubility temperature of approximately 151 C in PVC, compared to 129 C for DINP. That 22-degree difference means you need to run your mixer and extruder hotter than you would with DINP or DEHP. If you see incomplete gelation or surface roughness after switching to DINCH, check your processing temperatures before adjusting anything else.
Regulatory Approvals and Safety Profile
DINCH carries one of the broadest regulatory approval portfolios among non-phthalate plasticizers. EFSA approved it for food contact use in 2006, and it is listed as EU Food Contact Material substance 775 with a specific migration limit of 60 mg/kg. The European Pharmacopeia added DINCH approval in 2018, opening the door for medical device applications across the EU.
In medical applications, DINCH shows genuinely strong migration performance. In blood storage bags, DEHP migration is roughly five times greater than DINCH at day one. Over a 49-day storage period, switching from DEHP to DINCH bags reduces patient exposure by 39% to 87% depending on the blood product type. For blood-contact devices specifically, DINCH excels at minimizing red blood cell hemolysis — a critical parameter that general-purpose alternatives like DOTP do not match as effectively.
The safety profile deserves honest treatment, not promotional language. German population biomonitoring found that median daily DINCH intake in 2017 was 4,310 times below the tolerable daily intake (TDI). That is an enormous safety margin by any measure. However, the same monitoring data showed a constant increase in population DINCH exposure between 1999 and 2017 as the plasticizer gained market share. Newer laboratory studies have raised questions about lipid metabolism effects in aquatic models and cytotoxicity of DINCH metabolites in cell lines. These findings do not override decades of regulatory evaluation and in vivo mammalian safety data, but they do mean the safety conversation around DINCH is ongoing — not closed.
My recommendation: treat DINCH’s safety as well-supported by current evidence while acknowledging that continued monitoring is appropriate, not alarming. Any responsible formulator should stay current with regulatory updates.
When DINCH Is Worth the Premium
DINCH costs more than conventional alternatives. In practical formulation, you need approximately 40% loading to achieve the same flexibility that DEHP delivers at 30%. That higher loading, combined with DINCH’s higher per-unit price, works out to roughly 15% more overall formulation cost. For a high-volume manufacturer, that premium adds up fast.
The question is whether that premium buys you something you actually need. Here is how I think about it:
DINCH is the clear choice when:
- Your product contacts blood or blood components (hemolysis performance is genuinely superior)
- Regulatory requirements specifically call for DINCH or list it by name
- Your customer requires the broadest possible regulatory clearance portfolio across EU, US, and Asian markets
- The application involves prolonged skin contact with vulnerable populations (toys for children under three, neonatal medical devices)
DOTP is usually sufficient when:
- The application needs non-phthalate compliance but does not involve direct blood contact
- Cost sensitivity is high and the end-use regulation accepts multiple non-phthalate options
- High-temperature processing is required (DOTP handles heat better)
- US market availability matters — DINCH supply has historically been constrained in North America
In a structured comparison of medical PVC plasticizers across seven performance parameters — efficiency, cost, compatibility, chemical resistance, aging, migration, and hemolysis — DINCH and DOTP tied at an overall score of 22 out of 35. DINCH won decisively on hemolysis but scored poorly on efficiency and cost. Neither plasticizer is universally superior. Picking a single “best” component is less useful than balancing your full formulation.
One supply reality worth knowing: BASF manufactures DINCH under the Hexamoll brand and has historically dominated the market. Evonik offers an alternative cyclohexanoate product (ELATUR CH) manufactured at their Marl, Germany facility. If you are evaluating plasticizer suppliers, knowing that a second source exists gives you bargaining power and supply security.
Key Takeaways
DINCH earns its place in the non-phthalate toolbox, but it is a specialized tool — not a universal replacement. Its cyclohexanoate chemistry delivers genuine safety advantages backed by extensive regulatory approvals and strong migration data. The trade-offs are real: higher processing temperatures, higher loading requirements, and roughly 15% higher formulation cost.
Match the plasticizer to the application. For blood-contact medical devices and products requiring the broadest regulatory portfolio, DINCH is hard to beat. For general-purpose non-phthalate compliance, evaluate whether DOTP meets your requirements at lower cost before defaulting to DINCH. And whatever you choose, run a proper formulation trial — the processing window for DINCH is narrower than what most compounders are accustomed to.